LycoRed, a nutraceuticals company and global leader in added-value nutrients, nutrition research and technologies, announced the funding of a new clinical trial series focused on skin care and the potential impact of digestibles on erythema (skin redness as a result of sun exposure) and general wellness. LycoRed, which produces leading lycopene-based supplement Lyc-O-Mato™, invested $1,000,000 into the new clinical trial, already underway. This well-controlled human clinical trial will support LycoRed’s newest skin health and beauty technology Lyc-O-Derm™
“With this new trial, we are investing heavily in LycoRed’s own expertise and insight, and our proven research and technology in digestible skin care,” says Golan Raz, head of commercialization for North America.
“There is a powerful relationship between the foods we consume and their ability to protect our bodies, particularly our largest organ, the skin. We are excited about the potential of these trials and expect encouraging results in December 2014, when the interim analysis will be completed,” continues Raz.
The new clinical trial is the latest effort in LycoRed’s ongoing programs to conduct clinically responsible research that benefits consumer health and wellness regimes. Last year, the brand completed a clinical trial on the cardiovascular system, the results of which will be published late 2014.